Biopharma companies often use outdated data tools like Microsoft Excel, leading to fragmented and manual data processing. With the explosion of data in the industry, companies are looking to adopt more sophisticated digital technologies, such as the “digital twin,” to streamline data collection and analysis. A “digital data backbone” is being seen as essential to centralize and contextualize all data, especially for the rapid development of cell and gene therapies. The rise of automation will free up scientists to focus on cutting-edge science, and the switch to a digital backbone must be driven by both IT and scientists in a coordinated effort. Embracing these changes will accelerate the discovery and development of novel therapies in the biopharma industry.
Source link
How Digitizing Data Collection and Analysis in Biopharma Can Drive Better, Faster Insights
